Cancellation of General Meeting

Unless otherwise defined herein, the capitalised terms used in this announcement have the same meaning as those used in the Company's announcements released on 10 March 2026.

20 March 2026

Physiomics Plc

("Physiomics" or the "Company")

Cancellation of General Meeting

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that the General Meeting previously scheduled to convene at 10:00 a.m. on Tuesday 7 April 2026 at the Copthorne Hotel Slough-Windsor, Cippenham Lane, Slough, Berkshire, SL1 2YE will no longer take place.

Reason for cancellation 

The Company's Board has concluded that it is unnecessary to proceed with the General Meeting on 7 April 2026 for the following reasons:

· on 10 March 2026, the Company announced a proposed placing and retail offer (the "Placing") to raise up to approximately £500,000 at a placing price of 0.3 pence per share, conditional upon the passing of certain resolutions at the General Meeting scheduled for 7 April 2026;

· following a review by the Board of the terms and structure of that placing the Company cancelled the Placing and completed (subject to Admission only) a revised placing and retail offer at an increased placing price of 0.4 pence per share (the "Revised Placing"), as announced on 17 March 2026; and

· the resolutions that were to be proposed at the General Meeting on 7 April 2026 are no longer appropriate, as they were drafted to reflect the terms of the original Placing at 0.3 pence per share.

The Board believes that the Revised Placing is in the best interests of the Company and its shareholders as a whole.

Existing proxy appointments

Any proxy appointments that you have already submitted in respect of the General Meeting scheduled for 7 April 2026 will not be valid.

No action required

You do not need to take any action at this stage.

You should not attend at the Copthorne Hotel Slough-Windsor on 7 April 2026, as no meeting will be held on that date.

Further Information

If you have any questions about this cancellation or about your shareholding, please contact the Customer Support Centre of MUFG Corporate Markets, the Company's Registrars, on 0371 664 0300 or by email at [email protected]. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.

We thank you for your continued support of the Company.

Further information on the Company can be found on its website at www.physiomics.co.uk

The Company's LEI is 213800A71DSZ6ABMTQ91.

 Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.